Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: A multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

1. Provencio, M.
2. Cruz Mora, M.A.
3. Gómez-Codina, J.
4. Quero Blanco, C.
5. Llanos, M.
6. García-Arroyo, F.R.
7. De La Cruz, L.
8. Gumá Padró, J.
9. Delgado Pérez, J.R.
10. Sánchez, A.
11. Álvarez Cabellos, R.
12. Rueda, A.